Bulk Pharmaceutical API Sources for TEMODAR

Bulk Pharmaceutical API Sources for TEMODAR

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-850-406
Hangzhou APIChem Technology		AC-758
Vitas-M Laboratory		STK623541

Bulk Active Pharmaceutical Ingredient (API) Sources for TEMODAR

Last updated: February 20, 2026

What Are Approved API Manufacturers for TEMODAR (Temozolomide)?

TEMODAR (temozolomide) is a chemotherapeutic agent used primarily in the treatment of glioblastoma multiforme and anaplastic astrocytoma. It is marketed by Merck & Co. and is supplied as a capsule. The supply chain relies on a limited number of manufacturers capable of producing high-quality, GMP-compliant APIs.

Who Are the Major API Suppliers for TEMODAR?

The primary API suppliers for temozolomide are concentrated among a handful of organizations, including:

1. Merck KGaA and Its Contract Manufacturers

• Merck KGaA developed the original manufacturing process.
• The company produces and supplies API primarily from its own facilities or trusted contract manufacturing organizations (CMOs).

2. Contract Manufacturing Organizations (CMOs)

Several CMOs are qualified to produce temozolomide API under GMP conditions, including:

Supplier	Location	Capabilities	Notable Details
Hubei Wuchang Pharmaceutical Factory	China	API synthesis	Approved supplier for Merck/EMD Serono
Zhejiang Jiuzhou Pharmaceutical	China	API synthesis	Capable of large-scale production
Synthelabo (Sanofi)	France	Early developer	No longer active as a producer for new supplies

3. Other Potential Suppliers

• Suppliers from China and India with established GMP facilities capable of high-potency API synthesis.
• Some local Chinese manufacturers with cGMP certifications for API manufacturing.

Patent and Regulatory Status

• The patent for temozolomide expired globally by 2009, opening the market to generic API manufacturers.
• EMA, FDA, and other regulators require API suppliers to provide batch certification, purity analysis, and GMP compliance documentation.

Quality and Regulatory Requirements

Suppliers must meet the following:

• Good Manufacturing Practice (GMP) certification.
• Batch-to-batch consistency.
• Purity levels exceeding 99%.
• Clearance from regulatory agencies like FDA, EMA, and PMDA.

Supply Chain Considerations

• API sourcing for TEMODAR is limited to manufacturers with GMP compliance.
• Reliance on Chinese and Indian suppliers has increased due to cost competitiveness.
• Quality control is critical given the cytotoxic nature of the API, requiring specialized handling and documentation.

Key Takeaways

• TEMODAR API is predominantly supplied by Merck KGaA and a select group of GMP-certified CMOs.
• Chinese and Indian API manufacturers serve as significant sources, with increasing market share.
• Regulatory compliance and high purity standards govern API procurement.
• The expiration of patent protections has expanded the number of API suppliers but increased quality assurance scrutiny.
• Supply chain risks include geopolitical stability, manufacturing capacity constraints, and quality variation.

FAQs

1. Are there multiple suppliers for TEMODAR API approved by regulators?

Yes, but most are limited to GMP-certified producers in China, India, and select European facilities.

2. Does the API sourcing influence drug pricing or availability?

Yes. Limited supplier bases and regulatory hurdles can affect cost and supply stability.

3. Can new manufacturers enter the TEMODAR API market?

Yes, with GMP certification, process validation, and regulatory approval, though establishing supply chains is complex.

4. Are there approved APIs for generic TEMODAR?

Several generic API manufacturers have gained approval, especially in India and China.

5. How does API quality control impact clinical or commercial supply?

High purity and batch consistency are essential for safety and efficacy, making quality control integral to supply security.

References

1. European Medicines Agency. (2021). Temozolomide (EMA/336473/2021). https://www.ema.europa.eu
2. U.S. Food and Drug Administration. (2022). Summary Basis of Approval for Temodal. https://www.fda.gov
3. Global Data. (2022). Market and manufacturing analysis of temozolomide APIs.
4. Chinese Pharmacopoeia. (2020). API manufacturing standards for temozolomide.
5. Indian Pharmacopeia Commission. (2021). API manufacturing regulations.